Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

July 31, 2011

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Formoterol (OT)

9 μg/dose, Inhaled, twice daily for 52 weeks

Trial Locations (27)

Unknown

Research Site, Nagoya

Research Site, Akita

Research Site, Fukuoka

Research Site, Chitose

Research Site, Obihiro

Research Site, Sapporo

Research Site, Ako

Research Site, Kobe

Research Site, Hitachi

Research Site, Tsukuba

Research Site, Kanazawa

Research Site, Sakaidechō

Research Site, Fujisawa

Research Site, Kawasaki-shi

Research Site, Yokohama

Research Site, Kōshi

Research Site, Kyoto

Research Site, Nagaoka

Research Site, Saiki-shi

Research Site, Moriguchi

Research Site, Matsue

Research Site, Bunkyo

Research Site, Chūō

Research Site, Katsushika-ku

Research Site, Kodaira

Research Site, Setagaya City

Research Site, Tosima-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY